Eric C. Greig

  • Partner
  • Eeric.greig@lw.com
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
  • T +1.202.637.3330
  •  
 

Profile

Eric Greig, a partner in the Washington, D.C. office of Latham & Watkins, focuses his practice on healthcare regulatory, litigation, and transactional matters involving the medical device, pharmaceutical, clinical laboratory, and healthcare provider industries.

Mr. Greig provides counsel on a variety of healthcare regulatory and transactional matters, focusing primarily on issues involving the Centers for Medicare and Medicaid Services (CMS), the HHS Office of Inspector General (OIG), and commercial insurers. He advises clients in the development and execution of third-party reimbursement strategies for new and existing technologies; counsels on compliance with Medicare billing policies, fraud and abuse laws, and federal and state “sunshine” laws; and advocates on behalf of healthcare providers and suppliers in connection with regulatory matters before CMS as well as government audits and investigations.

Mr. Greig also advises private equity firms, investment banks, commercial lenders, and healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, and financing in the United States.

Mr. Greig is a member of the American Health Lawyers Association and the American Bar Association Health Law Section.

Thought Leadership

Mr. Greig writes and speaks frequently on a variety of healthcare and life sciences topics, including the impact of federal healthcare reform legislation and new reimbursement policies on healthcare providers, medical suppliers, and life sciences companies. Mr. Greig co-authored a chapter related to Medicare and Medicaid reimbursement for off-label uses of drugs and devices in the book Off-Label Communications: A Guide to Sales & Marketing Compliance, published by the Food and Drug Law Institute (FDLI). Additionally, he co-authored a chapter in the ABA Health Law Section’s Second Edition of E-Health, Privacy and Security Law concerning FDA regulation of e-health and mobile medical device applications.

Other recent thought leadership includes:

  • “ACA ‘Repeal and Replace’ Bill Merits Attention from Industry Stakeholders,” Latham & Watkins Client Alert (May 2017)
  • “21st Century Cures Act Brings Medicare Reimbursement and Policy Changes in 2017,” Latham & Watkins Client Alert (January 2017)
  • "Maintaining an Ongoing Reimbursement Campaign,” AdvaMed Reimbursement Workshop (September 2016)
  • “Managing Innovation in World of Growing Risk Sharing Among Payers and Providers,” AdvaMed Reimbursement Workshop (July 2016)
  • “CMS Finalizes Long-awaited Rule Implementing ACA’s Overpayment Reporting Requirements,” Latham & Watkins Client Alert (February 2016)
  • “CMS Proposes New Medicare Reporting and Payment System for Laboratories,” Latham & Watkins Client Alert (November 2015)
  • “CMS Adopts a New Framework that Significantly Reduces DMEPOS Fee Schedule Payments,” The Health Lawyer (February 2015)
  • “FDA to Strengthen Oversight of Certain In Vitro Diagnostic Devices,” Latham & Watkins Client Alert (August 2014)
  • “CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act,” Latham & Watkins Client Alert (February 2013)
  • “US Congress Delays Medicare Physician Pay Cut,” Latham & Watkins Client Alert (January 2013)
  • “Implications of Medicaid Expansion Under the Affordable Care Act,” Latham & Watkins Client Alert (July 2012)    

Thought Leadership

  • Healthcare & Life Sciences: Drug Pricing Digest -  May 09, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  April 25, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  April 11, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest -  March 28, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  March 14, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest -  February 28, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest -  February 14, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  January 31, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  January 17, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest -  January 04, 2022
  • Healthcare & Life Sciences: Drug Pricing Digest  -  December 20, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  December 06, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  November 22, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  November 08, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  October 25, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  October 11, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  September 27, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  September 13, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  August 30, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  August 16, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  August 02, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  July 19, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  July 06, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  June 22, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  June 07, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest  -  May 24, 2021
  • Healthcare & Life Sciences: Drug Pricing Digest -  May 10, 2021
  • Biden Administration Update: Potential Impact for Healthcare & Life Sciences -  January 21, 2021
  • CMS Expands Healthcare Delivery Options During COVID-19 Pandemic -  April 02, 2020
  • Expanded Medicare Payment Policy and CARES Act Provide Financial Relief for Healthcare Providers and Suppliers -  March 31, 2020
  • Drug Pricing and Payment Policy: Sweeping HHS Rebate Reform Proposal and First 2019 Congressional Hearings -  February 05, 2019
  • Drug Pricing and Payment Policy: Key 2018 Developments and Potential 2019 Changes and Challenges  -  January 07, 2019
  • ACA “Repeal and Replace” Bill Merits Attention from Industry Stakeholders -  May 09, 2017
  • 21st Century Cures Act Brings Medicare Reimbursement and Policy Changes in 2017 -  January 03, 2017
  • President Obama Signs the 21st Century Cures Act Into Law -  December 13, 2016
  • CMS Finalizes Long-awaited Rule Implementing ACA’s Overpayment Reporting Requirements  -  February 23, 2016
  • CMS Proposes New Medicare Reporting and Payment System for Laboratories -  November 06, 2015
  • CMS Adopts a New Framework that Significantly Reduces DMEPOS Fee Schedule Payments -  February 16, 2015
  • FDA to Strengthen Oversight of Certain In Vitro Diagnostic Devices -  August 20, 2014
  • CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act -  February 18, 2013
  • US Congress Delays Medicare Physician Pay Cut -  January 16, 2013
  • Implications of Medicaid Expansion Under the Affordable Care Act -  July 31, 2012
  • CMS Proposes Major Changes to Overpayment Reporting Requirements, Extending Liability to Ten Years -  March 7, 2012
  • The Institute of Medicine Recommends FDA Abandon the 510(k) Premarket Clearance Process -  August 2, 2011
  • FDA Moves to Clarify Nanotechnology Guidelines -  June 20, 2011
Bar Qualification
  • District of Columbia
  • Ohio
Education
  • JD, The University of Texas School of Law, 2010
    High Honors
  • BS, The Ohio State University, 2006
    cum laude
Industries
  • Healthcare & Life Sciences
Practices
  • Public Company Representation
  • Mergers & Acquisitions
  • White Collar Defense & Investigations
  • Emerging Companies
  • Private Equity